HQ Team
June 3, 2025: Billionaire Elon Musk’s Neuralink has raised $650 million in Series E funding from key investors and its clinical trials for brain implant devices have started in three countries.
The investors include ARK Invest, DFJ Growth, Founders Fund, G42, Human Capital and Lightspeed. Others were QIA, Sequoia Capital, Thrive Capital, Valor Equity Partners and Vy Capital.
“This funding helps us bring our technology to more people, restoring independence for those with unmet medical needs and pushing the boundaries of what’s possible with brain interfaces,” according to a statement.
The fresh funds will accelerate Neuralink’s efforts to expand patient access and innovate future devices that deepen the connection between biological and artificial intelligence.
Clinical trials begin
“Since our Series D in August 2023, we’ve made significant progress towards building brain interfaces to help restore independence and expand what’s possible for humanity.”
The company stated that five individuals with severe paralysis were now using Neuralink to control digital and physical devices with their thoughts, marking a profound step toward helping restore independence.
It has started clinical trials at leading institutions for neurosurgical care spanning three countries and two continents, including Barrow Neurological Institute, The Miami Project to Cure Paralysis at the University of Miami, University Health Network (Toronto Western Hospital), and the Cleveland Clinic Abu Dhabi.
‘Unlock human potential’
Neuralink has paved the way for applying its “technology to use cases beyond digital device control” by beginning a trial and securing the Food and Drug Administration’s Breakthrough Device Designation for both innovative vision and speech restoration programs.
The company has invested “heavily in expanding the number of neurons and brain regions that our device interfaces with to unlock new dimensions of human potential,” according to the statement.
Musk said recently that he was leaving his role as special adviser to US President Donald Trump to return his focus to his companies, including Tesla, SpaceX, xAI, Neuralink and social media platform X.
